Shares of Aura Biosciences, Inc. (NASDAQ:AURA – Get Free Report) gapped down before the market opened on Friday. The stock had previously closed at $6.98, but opened at $6.51. Aura Biosciences shares last traded at $6.9450, with a volume of 49,293 shares trading hands.
Wall Street Analysts Forecast Growth
A number of equities analysts have commented on AURA shares. Wall Street Zen upgraded shares of Aura Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, November 14th. Citigroup reaffirmed a “market outperform” rating on shares of Aura Biosciences in a research note on Tuesday, November 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aura Biosciences in a report on Monday, October 12th. Finally, HC Wainwright cut their target price on shares of Aura Biosciences from $24.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $17.50.
Get Our Latest Stock Report on Aura Biosciences
Aura Biosciences Stock Performance
Aura Biosciences (NASDAQ:AURA – Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.08. As a group, research analysts forecast that Aura Biosciences, Inc. will post -1.48 EPS for the current year.
Hedge Funds Weigh In On Aura Biosciences
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. American Century Companies Inc. acquired a new position in Aura Biosciences in the third quarter valued at about $344,000. Algert Global LLC acquired a new position in shares of Aura Biosciences during the 3rd quarter worth about $565,000. Goldman Sachs Group Inc. grew its position in shares of Aura Biosciences by 103.4% during the 3rd quarter. Goldman Sachs Group Inc. now owns 944,951 shares of the company’s stock worth $5,934,000 after buying an additional 480,283 shares during the period. Bellevue Group AG grew its position in shares of Aura Biosciences by 21.5% during the 3rd quarter. Bellevue Group AG now owns 1,418,014 shares of the company’s stock worth $8,905,000 after buying an additional 251,347 shares during the period. Finally, Entropy Technologies LP acquired a new position in shares of Aura Biosciences during the 3rd quarter worth about $242,000. 96.75% of the stock is owned by institutional investors.
Aura Biosciences Company Profile
Aura Biosciences is a clinical-stage biotechnology company developing treatments for cancer, with a focus on therapies designed to selectively destroy tumor cells while limiting damage to surrounding healthy tissue. The company is headquartered in the Boston area. Its lead candidate, belzupacap sarotalocan (formerly AU-011), is an investigational therapy being studied for choroidal melanoma, a cancer that develops in the eye. It uses a virus-like particle linked to a light-activated compound; after the compound binds to tumor cells, near-infrared light activates it to damage those cells.
Read More
- Five stocks we like better than Aura Biosciences
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
